• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk Factors for Persistent or Recurrent Central Serous Chorioretinopathy.持续性或复发性中心性浆液性脉络膜视网膜病变的危险因素。
J Ophthalmol. 2019 Aug 14;2019:5970659. doi: 10.1155/2019/5970659. eCollection 2019.
2
Selective Retina Therapy in Acute and Chronic-Recurrent Central Serous Chorioretinopathy.急性和慢性复发性中心性浆液性脉络膜视网膜病变的选择性视网膜治疗
Ophthalmologica. 2015;234(4):177-88. doi: 10.1159/000439188. Epub 2015 Sep 15.
3
The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case-control study.急性中心性浆液性脉络膜视网膜病变自发消退及低能量光动力治疗后的消退时间和复发率:一项病例对照研究
Eye (Lond). 2016 Jul;30(7):1005-10. doi: 10.1038/eye.2016.79. Epub 2016 Apr 22.
4
Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy.光动力疗法后脉络膜厚度变化与慢性中心性浆液性脉络膜视网膜病变的复发
Am J Ophthalmol. 2015 Jul;160(1):72-84.e1. doi: 10.1016/j.ajo.2015.04.011. Epub 2015 Apr 14.
5
Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.对低剂量光动力疗法反应不足的慢性中心性浆液性脉络膜视网膜病变患者的临床特征
Graefes Arch Clin Exp Ophthalmol. 2018 Aug;256(8):1395-1402. doi: 10.1007/s00417-018-4003-z. Epub 2018 May 7.
6
Modified Photodynamic Therapy Treatment of Central Serous Chorioretinopathy.改良光动力疗法治疗中心性浆液性脉络膜视网膜病变
Optom Vis Sci. 2016 Jul;93(7):760-71. doi: 10.1097/OPX.0000000000000864.
7
Treatment and Monitoring of Central Serous Chorioretinopathy in Pilots.飞行员中心性浆液性脉络膜视网膜病变的治疗与监测
Aerosp Med Hum Perform. 2016 Dec 1;87(12):1041-1044. doi: 10.3357/AMHP.4671.2016.
8
Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy.评价选择性视网膜治疗激光治疗中心性浆液性脉络膜视网膜病变患者的安全性和疗效。
Korean J Ophthalmol. 2021 Feb;35(1):51-63. doi: 10.3341/kjo.2020.0112. Epub 2020 Dec 11.
9
SUBFOVEAL CHOROIDAL THICKNESS CHANGES IN TREATED IDIOPATHIC CENTRAL SEROUS CHORIORETINOPATHY AND THEIR ASSOCIATION WITH RECURRENCE.治疗后的特发性中心性浆液性脉络膜视网膜病变黄斑下脉络膜厚度变化及其与复发的关系
Retina. 2015 Sep;35(9):1867-74. doi: 10.1097/IAE.0000000000000557.
10
Role of Avastin in management of central serous chorioretinopathy.阿瓦斯汀在中心性浆液性脉络膜视网膜病变治疗中的作用。
Saudi J Ophthalmol. 2010 Jul;24(3):69-75. doi: 10.1016/j.sjopt.2010.03.002. Epub 2010 Oct 4.

引用本文的文献

1
Central Serous Chorioretinopathy Risk Factors in An Iranian Cohort: A Case-control Study.伊朗队列中中心性浆液性脉络膜视网膜病变的危险因素:一项病例对照研究。
J Ophthalmic Vis Res. 2023 Nov 30;18(4):410-416. doi: 10.18502/jovr.v18i4.14553. eCollection 2023 Oct-Dec.
2
Changes in Aqueous Concentrations of Various Cytokines after Intravitreal Bevacizumab Injection for Chronic Central Serous Chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变玻璃体内注射贝伐单抗后房水中各种细胞因子浓度的变化。
Korean J Ophthalmol. 2023 Dec;37(6):453-461. doi: 10.3341/kjo.2023.0005. Epub 2023 Oct 25.
3
Functional Outcomes and Safety Profile of Trans-Foveal Subthreshold Micropulse Laser in Persistent Central Serous Chorioretinopathy.经黄斑中心凹阈下微脉冲激光治疗持续性中心性浆液性脉络膜视网膜病变的功能预后和安全性概况
Life (Basel). 2023 May 16;13(5):1194. doi: 10.3390/life13051194.
4
Diagnostic and Therapeutic Challenges in a Patient with Radiation Retinopathy Complicated by Corticosteroid-Induced Central Serous Chorioretinopathy.放射性视网膜病变合并皮质类固醇诱导性中心性浆液性脉络膜视网膜病变患者的诊断和治疗挑战。
Medicina (Kaunas). 2022 Jun 28;58(7):862. doi: 10.3390/medicina58070862.
5
Longitudinal follow-up and outcome analysis in central serous chorioretinopathy.中浆病的纵向随访和结局分析。
Eye (Lond). 2023 Mar;37(4):732-738. doi: 10.1038/s41433-022-02044-z. Epub 2022 Apr 1.
6
Clinical Characteristics of Pregnancy-Associated Central Serous Chorioretinopathy in the Chinese Population.中国人群妊娠相关性中心性浆液性脉络膜视网膜病变的临床特征
J Ophthalmol. 2021 Dec 16;2021:5580075. doi: 10.1155/2021/5580075. eCollection 2021.
7
Predicting Central Serous Chorioretinopathy Recurrence Using Machine Learning.使用机器学习预测中心性浆液性脉络膜视网膜病变的复发
Front Physiol. 2021 Nov 25;12:649316. doi: 10.3389/fphys.2021.649316. eCollection 2021.
8
Deep Learning for Detecting Subretinal Fluid and Discerning Macular Status by Fundus Images in Central Serous Chorioretinopathy.深度学习用于通过中心性浆液性脉络膜视网膜病变的眼底图像检测视网膜下液并识别黄斑状态
Front Bioeng Biotechnol. 2021 Nov 5;9:651340. doi: 10.3389/fbioe.2021.651340. eCollection 2021.
9
Sharing the Same Perspective. Mental Disorders and Central Serous Chorioretinopathy: A Systematic Review of Evidence from 2010 to 2020.观点一致。精神障碍与中心性浆液性脉络膜视网膜病变:2010年至2020年证据的系统评价
Biomedicines. 2021 Aug 23;9(8):1067. doi: 10.3390/biomedicines9081067.
10
Central Serous Chorioretinopathy and Personality Characteristics: A Systematic Review of Scientific Evidence over the Last 10 Years (2010 to 2020).中心性浆液性脉络膜视网膜病变与人格特征:过去 10 年(2010 至 2020 年)科学证据的系统回顾。
Medicina (Kaunas). 2021 Jun 16;57(6):628. doi: 10.3390/medicina57060628.

本文引用的文献

1
Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变的长期视力结果和致盲原因。
Ophthalmology. 2019 Apr;126(4):576-588. doi: 10.1016/j.ophtha.2018.12.048. Epub 2019 Jan 17.
2
Poor Sleep Quality Is the Risk Factor for Central Serous Chorioretinopathy.睡眠质量差是中心性浆液性脉络膜视网膜病变的危险因素。
J Ophthalmol. 2018 Aug 1;2018:9450297. doi: 10.1155/2018/9450297. eCollection 2018.
3
Association of Central Serous Chorioretinopathy with Psychosocial Factors is Dependent on Its Phase and Subtype.中心性浆液性脉络膜视网膜病变与心理社会因素的关联取决于其阶段和亚型。
Korean J Ophthalmol. 2018 Aug;32(4):281-289. doi: 10.3341/kjo.2017.0144.
4
Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients.患者特征和中心性浆液性脉络膜视网膜病变的危险因素:811 例患者分析。
Br J Ophthalmol. 2019 Jun;103(6):725-729. doi: 10.1136/bjophthalmol-2018-312431. Epub 2018 Jul 12.
5
Gender variation in central serous chorioretinopathy.中心性浆液性脉络膜视网膜病变的性别差异。
Eye (Lond). 2018 Nov;32(11):1703-1709. doi: 10.1038/s41433-018-0163-7. Epub 2018 Jul 9.
6
The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels.中心性浆液性脉络膜视网膜病变、脉络膜厚度与血清激素水平之间的关系。
Graefes Arch Clin Exp Ophthalmol. 2018 Jun;256(6):1111-1116. doi: 10.1007/s00417-018-3985-x. Epub 2018 Apr 18.
7
RISK FACTORS FOR RECURRENCES OF CENTRAL SEROUS CHORIORETINOPATHY.中浆病复发的风险因素。
Retina. 2018 Jul;38(7):1403-1414. doi: 10.1097/IAE.0000000000001729.
8
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).依普利酮治疗中心性浆液性脉络膜视网膜病变(ECSelsior)的随机双盲安慰剂对照初步研究。
Retina. 2018 May;38(5):962-969. doi: 10.1097/IAE.0000000000001649.
9
Risk Factors for Central Serous Chorioretinopathy: Multivariate Approach in a Case-Control Study.中心性浆液性脉络膜视网膜病变的危险因素:病例对照研究中的多变量分析方法
Curr Eye Res. 2017 Jul;42(7):1069-1073. doi: 10.1080/02713683.2016.1276196. Epub 2017 Mar 17.
10
ACUTE CENTRAL SEROUS CHORIORETINOPATHY: Factors Influencing Episode Duration.急性中心性浆液性脉络膜视网膜病变:影响病程持续时间的因素
Retina. 2017 Oct;37(10):1905-1915. doi: 10.1097/IAE.0000000000001443.

持续性或复发性中心性浆液性脉络膜视网膜病变的危险因素。

Risk Factors for Persistent or Recurrent Central Serous Chorioretinopathy.

作者信息

Yu Jia, Xu Gezhi, Chang Qing, Ye Xiaofeng, Li Lei, Jiang Chunhui, Zhao Qi

机构信息

Department of Ophthalmology, Eye & Ear Nose Throat Hospital of Fudan University, Shanghai 200031, China.

Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai 200031, China.

出版信息

J Ophthalmol. 2019 Aug 14;2019:5970659. doi: 10.1155/2019/5970659. eCollection 2019.

DOI:10.1155/2019/5970659
PMID:31485346
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6710733/
Abstract

PURPOSE

To investigate the risk factors for persistent or recurrent central serous chorioretinopathy (CSC).

MATERIALS AND METHODS

Consecutive treatment-naïve CSC patients were included from January 2017 to October 2018. All patients were asked to complete questionnaires, addressing previously described risk factors for the development of CSC. Patients were divided into two groups: those with acute CSC, who were in the first episode, with spontaneous resolution of subretinal fluid within 3 months, and with no recurrence within 1 year; and those with persistent or recurrent CSC, the remaining patients.

RESULTS

In total, 138 patients were enrolled: 20 (14.5%) with acute CSC and 118 (85.5%) with persistent or recurrent CSC. Using multivariate analysis, male sex (odds ratio (OR), 95% confidence interval: 5.63 [1.02-31.02]; =0.047), older age (OR: 1.14 [1.03-1.25]; =0.008), and higher Insomnia Severity Index score (OR: 1.30 [1.05-1.60]; =0.015) were found to be independently associated with persistent or recurrent CSC.

CONCLUSIONS

Male sex, age, and sleep disorders are risk factors for persistent or recurrent CSC in the natural history. These patients may require early photodynamic therapy. Treatment for sleep disorders is strongly recommended. All CSC patients may require careful and periodic follow-up.

摘要

目的

探讨持续性或复发性中心性浆液性脉络膜视网膜病变(CSC)的危险因素。

材料与方法

纳入2017年1月至2018年10月连续未经治疗的CSC患者。所有患者均被要求完成问卷,问卷涉及先前描述的CSC发生的危险因素。患者被分为两组:急性CSC组,即首次发病,视网膜下液在3个月内自发消退且1年内无复发的患者;持续性或复发性CSC组,即其余患者。

结果

共纳入138例患者:20例(14.5%)为急性CSC,118例(85.5%)为持续性或复发性CSC。采用多因素分析,发现男性(比值比(OR),95%置信区间:5.63[1.02 - 31.02];P = 0.047)、年龄较大(OR:1.14[1.03 - 1.25];P = 0.008)以及失眠严重程度指数得分较高(OR:1.30[1.05 - 1.60];P = 0.015)与持续性或复发性CSC独立相关。

结论

男性、年龄和睡眠障碍是自然病程中持续性或复发性CSC的危险因素。这些患者可能需要早期光动力治疗。强烈建议对睡眠障碍进行治疗。所有CSC患者可能都需要仔细且定期的随访。